Saturday, 5 Dec 2020

First Solar Q3 Results Top Estimates; Reinstates Q4 Guidance

Trump Website Briefly Defaced, Promoted Crypto Scam

One of Donald Trump’s campaign websites, donaldjtrump.com, was briefly made to look like it had been seized by law enforcement Tuesday, an effort that appeared to be part of a cryptocurrency scam.

The takeover, termed a defacement by cybersecurity experts, lasted for less than an hour. During that time, the web page was made to look like it had been take over by the government and included images of Federal Bureau of Investigation and Justice Department seals. It also included a message urging people to send digital currency to an account, a technique used by criminals.

It is unknown who caused the defacement, or if the Trump website was hacked. A website defacement doesn’t necessarily mean information from the site was taken. TechCrunch previously reported the incident.

A Trump campaign spokesman said that no sensitive data was at risk.

“Earlier this evening, the Trump campaign website was defaced and we are working with law enforcement authorities to investigate the source of the attack,” spokesman Tim Murtaugh said. “There was no exposure to sensitive data because none of it is actually stored on the site. The website has been restored.”

MorphoSys Raises 2020 Outlook

MorphoSys AG (MOR,MPSYY.PK) said that it raised its outlook for the financial year 2020, due to higher revenues from partnerships and collaborations and Tremfya royalties are expected to be at the upper end of guidance.

The updated guidance now also includes revenues from product sales of Monjuvi following its approval and subsequent launch in the U.S.

For 2020, the company now expects an EBIT to be in the range of 10 million euros to 20 million euros compared to the prior estimation of negative 15 million euros to positive 5 million euros.

The company projects annual group revenues to be in the range of 317 million euros – 327 million euros compared to the prior outlook of 280 million euros – 290 million euros.

In the first nine months of 2020, MorphoSys reported preliminary group revenues of 291.7 million euros and an EBIT of 101.8 million million euros.

The company will publish its third-quarter results on November 11.

Qiagen Q3 Results Top Estimates; Lifts 2020 Outlook

Qiagen N.V. (QGEN) reported that its third-quarter net income was $16.91 million or $0.07 per share compared to a loss of $160.64 million or $0.71 per share in the previous year.

Adjusted earnings per share were $0.58, compared to $0.36 per share last year. Analysts polled by Thomson Reuters expected the company to report earnings of $0.56 per share. Analysts’ estimates typically exclude special items.

Sales for the third quarter of 2020 rose 26% at actual rates, and also rose 26% at constant exchange rates, to $483.8 million from $382.7 million in the same period of 2019. Analysts expected revenue of $462.79 million for the quarter.

For the fourth-quarter, the company expects net sales growth of about 24-27% CER and for adjusted earnings per share to reach $0.58-$0.60 CER. Analysts project fourth-quarter earnings of $0.66 per share.

For full-year 2020, the company now expects adjusted earnings per share to grow about 45% CER to at about $2.07- $2.09 CER from $1.43 in 2019. Previously, it expected at least 40% growth in adjusted earnings per share to at least $2.00 CER. Analysts expect annual earnings of $2.06 per share.

The company now expects annual sales growth of about 20% at constant exchange rates from the 2019 level of $1.53 billion. Previously, it expected annual sales growth of 15%-18% at constant exchange rates.

Ultragenyx Pharma Q3 Loss Narrows

Ultragenyx Pharmaceutical Inc. (RARE) reported that its third-quarter net loss narrowed to $68.8 million or $1.13 per share, from $113.0 million or $1.96 per share last year.

Quarterly revenues were $81.5 million up from $25.8 million in the previous year.
Ultragenyx recognized $37.3 million in total Crysvita revenue in the Ultragenyx territories, which includes $34.1 million in collaboration revenue in the North American profit share territory and net product sales in other regions of $3.3 million.

Analysts polled by Thomson Reuters expected the company to report a loss of $1.27 per share and revenues of $53.89 million for the quarter. Analysts’ estimates typically exclude special items.

The lower end of the range for 2020 Crysvita revenue in Ultragenyx territories has been increased to $130.0 million from $125.0 million. The updated guidance range is $130.0 million to $140.0 million.

First Solar Q3 Results Top Estimates; Reinstates Q4 Guidance

First Solar Inc. (FSLR) reported that its third-quarter net income surged to $155.04 million or $1.45 per share from $30.62 million or $0.29 per share in the previous year. Analysts polled by Thomson Reuters expected the company to report earnings of $0.61 per share for the quarter. Analysts’ estimates typically exclude special items.

Net sales for the third quarter were $927.57 million, up from $546.81 million in the previous year. Analysts expected revenue of $693.13 million for the quarter.

The company reinstated financial guidance for the fourth quarter 2020 and provided implied full-year 2020 guidance. The company previously withdrew its full-year 2020 guidance on May 7, 2020 citing the significant uncertainties regarding the severity and duration of the COVID-19 pandemic.

For the fourth-quarter, the company expects earnings per share to be in the range of $1.00 to $1.50, and net sales of $540 million to $790 million. Analysts expect the company to report earnings of $1.07 per share and revenues of $814.63 million for the fourth-quarter.

Looking ahead for 2020, the company projects earnings per share to be in the range of $3.65 to $4.15 and net sales of $2.6 billion to $2.9 billion. Wall Street currently is looking for fiscal year 2020 earnings of $2.86 per share on annual revenues of $2.67 billion.

Related Posts